Menin-MLL inhibitor blocks progression of middle ear cholesteatoma in vivo

• Published in: International journal of pediatric otorhinolaryngology Vol. 140; p. 110545
• Main Authors: Yamamoto-Fukuda, Tomomi, Akiyama, Naotaro, Tatsumi, Norifumi, Okabe, Masataka, Kojima, Hiromi
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.01.2021
• Subjects: Cholesteatoma; KGF; Level of evidence: N/A; Menin-MLL inhibitor; p63; Level of evidence: N/A; KGF; Cholesteatoma; p63; Menin-MLL inhibitor
• ISSN: 0165-5876; 1872-8464
• DOI: 10.1016/j.ijporl.2020.110545

Cholesteatoma is an epithelial lesion that expands into the middle ear, resulting in bone destruction. The acceleration of the proliferative activity of epithelial stem/progenitor cells is involved in the pathogenesis of cholesteatoma. Recently, the use of a menin-mixed lineage leukemia 1 (MLL1) inhibitor, MI503, in experiments has resulted in inhibition of the growth of tumors under histone modification. In this study, we investigated the effects of the menin-MLL inhibitor against cholesteatoma growth in an in vivo model. We first correlated the expression level of histone H3 trimethylation at lysine 4 (H3K4me3) among cholesteatoma cases, chronic otitis media cases and normal skin tissues. Based on the role of keratinocyte growth factor (KGF) in the development of cholesteatoma, KGF-expression vector was transfected into the ear and we analyzed the expression level of H3K4me3. After cholesteatoma was induced, MI503 was administered daily into the ear for 14 days. We detected the highest labeling index of H3K4me3 in the cholesteatoma specimens. After KGF-expression vector transfection in the mouse ear, a high expression level of H3K4me3 was observed in the epithelial layers. The use of MI503 reduced cholesteatoma in the in vivo model and decreased the proliferation of epithelial stem/progenitor cells in a dose-dependent manner. We demonstrated that inhibition of the menin-MLL interaction may be a potentially useful strategy in the conservative treatment of cholesteatoma.